Cardiac biomarkers alterations in patients with SARS-CoV-2 infection

Rom J Intern Med. 2022 Mar 17;60(1):6-13. doi: 10.2478/rjim-2021-0037. Print 2022 Mar 1.

Abstract

Reliable biomarkers are necessary for the risk stratification of patients infected with SARS-CoV-2. This novel coronavirus is now established to affect several organs in addition to the lungs, most prominently the heart. This is achieved through direct damage to the myocardium and indirect immune-associated effects during the cytokine storm. We performed a literature review aiming to identify the prognostic value of alterations of cardiac biomarkers in SARS-CoV-2 infection. Cardiac biomarkers are significantly elevated in patients with severe COVID-19 and are independent predictors of mortality. High-sensitivity troponin I and T are correlated with multiple inflammatory indexes and poor outcomes. Although cut-off values have been established for most of cardiac biomarkers, lower limits for troponins may have better prognostic values and longitudinal monitoring of cardiac biomarkers can help the clinician assess the patient's course. Additional measurements of NT-proBNP, can detect the subgroup of patients with poor prognosis.

Keywords: SARS-CoV-2; biomarkers; natriuritic peptides; prognosis; troponins.

Publication types

  • Review

MeSH terms

  • Biomarkers / blood
  • COVID-19* / complications
  • Heart Diseases / virology*
  • Humans
  • Prognosis
  • SARS-CoV-2
  • Troponin I / blood*
  • Troponin T / blood*

Substances

  • Biomarkers
  • Troponin I
  • Troponin T